Literature DB >> 23381448

Management of the new patient with CML in chronic phase.

David Marin1.   

Abstract

Imatinib has been the preferred initial therapy for newly diagnosed chronic myeloid leukemia (CML) patients for the last 10 years. Today, other tyrosine kinase inhibitors (TKIs) are licensed for first-line use. In this paper we analyze the pros and cons of the various alternatives to imatinib and try to give some advice on the management of the newly diagnosed patient.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23381448     DOI： 10.1007/s11899-012-0151-0

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


  23 in total

1.  Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

Authors:  Hagop M Kantarjian; Neil P Shah; Jorge E Cortes; Michele Baccarani; Mohan B Agarwal; María Soledad Undurraga; Jianxiang Wang; Juan Julio Kassack Ipiña; Dong-Wook Kim; Michinori Ogura; Carolina Pavlovsky; Christian Junghanss; Jorge H Milone; Franck E Nicolini; Tadeusz Robak; Jan Van Droogenbroeck; Edo Vellenga; M Brigid Bradley-Garelik; Chao Zhu; Andreas Hochhaus
Journal:  Blood       Date:  2011-12-09       Impact factor: 22.113

Review 2.  Current status of imatinib as frontline therapy for chronic myeloid leukemia.

Authors:  David Marin
Journal:  Semin Hematol       Date:  2010-10       Impact factor: 3.851

3.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Authors:  François-Xavier Mahon; Delphine Réa; Joëlle Guilhot; François Guilhot; Françoise Huguet; Franck Nicolini; Laurence Legros; Aude Charbonnier; Agnès Guerci; Bruno Varet; Gabriel Etienne; Josy Reiffers; Philippe Rousselot
Journal:  Lancet Oncol       Date:  2010-10-19       Impact factor: 41.316

4.  Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy.

Authors:  Dongho Kim; Hyun-Gyung Goh; Soo-Hyun Kim; Byung-Sik Cho; Dong-Wook Kim
Journal:  Int J Hematol       Date:  2011-09-08       Impact factor: 2.490

5.  Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?

Authors:  Elias Jabbour; Hagop M Kantarjian; Susan O'Brien; Jianqin Shan; Alfonso Quintás-Cardama; Guillermo Garcia-Manero; Mary Beth Rios; Jorge E Cortes
Journal:  J Clin Oncol       Date:  2011-10-11       Impact factor: 44.544

6.  Correlation between the proportion of Philadelphia chromosome-positive metaphase cells and levels of BCR-ABL mRNA in chronic myeloid leukaemia.

Authors:  F Lin; A Chase; J Bungey; J M Goldman; N C Cross
Journal:  Genes Chromosomes Cancer       Date:  1995-06       Impact factor: 5.006

7.  Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion.

Authors:  Kimmo Porkka; H Jean Khoury; Ronald L Paquette; Yousif Matloub; Ritwik Sinha; Jorge E Cortes
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860

8.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Authors:  Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

Review 9.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

Authors:  Michele Baccarani; Jorge Cortes; Fabrizio Pane; Dietger Niederwieser; Giuseppe Saglio; Jane Apperley; Francisco Cervantes; Michael Deininger; Alois Gratwohl; François Guilhot; Andreas Hochhaus; Mary Horowitz; Timothy Hughes; Hagop Kantarjian; Richard Larson; Jerald Radich; Bengt Simonsson; Richard T Silver; John Goldman; Rudiger Hehlmann
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

10.  Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.

Authors:  Jorge E Cortes; Dan Jones; Susan O'Brien; Elias Jabbour; Marina Konopleva; Alessandra Ferrajoli; Tapan Kadia; Gautam Borthakur; Denise Stigliano; Jianqin Shan; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544
View more
  1 in total

1.  Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort.

Authors:  A G Smith; D Painter; D A Howell; P Evans; G Smith; R Patmore; A Jack; E Roman
Journal:  BMJ Open       Date:  2014-01-15       Impact factor: 2.692
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.